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Abstract
Background Phase 3 clinical trial results reveal that
Qsymia is a clinically effective long-term treatment for
obesity, but whether this treatment is cost-effective com-
pared to a diet and lifestyle intervention has yet to be
explored.
Objective To quantify the incremental cost-effectiveness
of Qsymia (phentermine and topiramate extended-release)
for health-related quality of life improvements.
Study design and methods Estimates are based on cost
and quality of life outcomes from a 56-week, multicenter,
placebo-controlled, phase 3 clinical trial undertaken in 93
health centers in the US. Participants were overweight and
obese adults (aged 18–70 years) with a body-mass index of
27–45 kg/m2 and two or more comorbidities (hypertension,
dyslipidemia, diabetes or pre-diabetes or abdominal obes-
ity). The intervention was diet and lifestyle advice plus the
recommended dose of Qsymia (phentermine 7.5 mg plus
topiramate 46.0 mg) vs. control, which included diet and
lifestyle advice plus placebo. The study was from the payer
perspective. Costs included the prescription cost, medica-
tion cost offsets and physician appointment costs.
Effectiveness was measured in terms of quality-adjusted
life years gained (QALYs). The main outcome measure
was incremental cost per QALY gained of the intervention
relative to control.
Results Our base-case model, in which participants take
Qsymia for 1 year with benefits linearly decaying over the
subsequent 2 years, generates an incremental cost-effec-
tiveness ratio (ICER) of $48,340 per QALY gained. Using
the base-case assumptions, probabilistic sensitivity analy-
ses reveal that the ICER is below $50,000 per QALY in
54 % of simulations. However, results are highly depen-
dent on the extent to which benefits are maintained post
medication cessation. If benefits persist for only 1 year post
cessation, the ICER increases to $74,480.
Conclusion Although base-case results suggest that Qsy-
mia is cost-effective, this result hinges on the time on Qsymia
and the extent to which benefits are maintained post medi-
cation cessation. This should be an area of future research.
Key Points for Decision Makers
Given the obesity epidemic, decision makers are
looking to identify cost-effective strategies to
improve the health of their obese members.
Few effective medical interventions for weight loss
are available.
These results show that, in addition to clinically
significant weight loss, Qsymia generates
improvements in quality of life and reductions in
medication costs.
If benefits persist beyond medication cessation,
results suggest that Qsymia may be a cost-effective
nonsurgical alternative for weight management.
Electronic supplementary material The online version of this
article (doi:10.1007/s40273-014-0182-6) contains supplementary
material, which is available to authorized users.
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Obesity is a major risk factor for a number of adverse
health conditions, including type 2 diabetes, heart disease,
and cancer [1]. Further, worldwide obesity rates have more
than doubled in the past 3 decades, such that excess weight
is now the fifth leading risk for global deaths, accounting
for roughly 2.8 million deaths each year [2].
In addition to the health effects, obesity imposes sig-
nificant external costs on society. For example, in the
United States (US) alone, annual medical expenditures for
treating obesity-related health conditions now exceed
$147 billion per year, with roughly half of this total
directly financed by Medicare and Medicaid [3]. Other
research shows that an obese worker has annual direct and
indirect costs that are between $1,143 (class I obese male)
and $6,694 (class II obese female) greater than costs for
their normal-weight counterparts, depending on gender
and degree of excess weight [4]. Moreover, the indirect
costs of obesity, which result from workloss due to
absenteeism and presenteeism, exceed the direct medical
costs.
Due to these impacts of obesity on society, there are
significant health and economic benefits that could be
accrued to individuals, governments, insurers, and
employers through successful weight-loss initiatives. Typ-
ically, the first line of treatment for excess weight is life-
style modification [5]. However, on average, lifestyle
interventions generate only modest weight loss [6], and this
weight loss is rarely maintained long term [7]. Bariatric
(weight loss) surgery is an effective treatment for severe
obesity [8], but due to its high cost (at least $20 K for the
surgery alone) and invasive nature, few obese individuals
have opted for this strategy. Roughly 113,000 weight-loss
surgeries are performed yearly in the US [9], and yet this
number is dwarfed by the obese population—estimated to
be over 80 million adults [10, 11].
Until recently, pharmacologic interventions for
addressing chronic weight management have been limited.
The drug combination fenfluramine/phentermine, referred
to as fen-phen, was the first commercially successful
weight loss drug. Although it was highly effective, it was
later shown to have potentially fatal side effects, which led
to its withdrawal from the market in 1997 [12]. Over the
next 15 years, only two weight-loss prescription medica-
tions were widely available on the US market, sibutramine
(Meridia) and orlistat (Xenical). Sibutramine was subse-
quently pulled from the market due to increased risk of
cardiovascular events [13]. Until 2012, only orlistat was
available for chronic use, but the weight loss observed in
clinical trials was only a few percentage points greater than
that seen with a placebo, and is associated with gastroin-
testinal side effects that limit its appeal [14, 15].
However, in 2012, the US FDA approved two new
therapies for chronic weight management: Belviq (lorcas-
erin) and Qsymia (phentermine plus topiramate extended-
release), to be used in combination with diet and exercise.
In a 1-year clinical trial, Qsymia phentermine 7.5 and to-
piramate 46 mg (recommended dose per label) [16], in
conjunction with diet and exercise, generated a clinically
significant weight loss of 6.6 % of body weight relative to
diet and exercise plus placebo [17]. Statistically significant
improvements with the Qsymia recommended dose com-
pared with placebo were also noted in blood pressure, waist
circumference, lipids, glycemic parameters, and inflam-
matory biomarkers. Moreover, rates of discontinuation
with Qsymia were lower than with placebo, suggesting
Qsymia has a tolerable side-effect profile. A follow-up
study showed that weight loss was maintained after 2 years
[18].
These results suggest that Qsymia is effective at
inducing weight loss and improving risk factors associated
with comorbidities. However, the incremental cost-effec-
tiveness of Qsymia compared to diet and exercise alone
remains unknown. Therefore, the objective of this study
was to assess the long-term cost-effectiveness of the rec-
ommended dose of Qsymia from the payer perspective.
Although the Centers for Medicare and Medicaid Services
(CMS) has maintained a policy of not considering cost-
effectiveness in national coverage decisions [19, 20], pri-
vate insurers and large employers do not face such a
restriction and have relied on cost-effectiveness analyses to
inform decision making. For example, UnitedHealth Group
now provides coverage for health coaches at YMCAs to
work with overweight patients at high risk for type 2 dia-
betes based on research showing that this approach is likely
to be cost-effective [21]. Because of pressure to provide
pharmacologic treatments for obesity as a covered benefit,
some insurers/employers will be interested to know whe-




This study utilized the effectiveness results from the
CONQUER randomized controlled trial. A complete
description of the trial is available elsewhere [17]. In brief,
CONQUER was a 56-week randomized, double-blind,
placebo-controlled trial conducted at 93 health centers in
the USA to determine the effectiveness of Qsymia for
weight loss and weight-related comorbidities. The trial was
undertaken between November 1, 2007 and June 30, 2009.
Adult participants were eligible if they were overweight or
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obese with a body-mass index (BMI) between 27 and
45 kg/m2 and at least two obesity related co-morbidities,
including increased waist circumference, elevated blood
pressure, elevated cholesterol or type 2 diabetes managed
with lifestyle modification or metformin. For those with
type 2 diabetes, no lower BMI limit was applicable. Full
inclusion and exclusion criteria were previously published
[17].
Eligible participants were stratified by gender and dia-
betes status and then randomly assigned in a 2:1:2 ratio to
the placebo arm, the phentermine 7.5 mg plus topiramate
extended-release 46 mg arm (Qsymia recommended dose),
and the phentermine 15 mg plus topiramate extended-
release 92 mg arm (Qsymia top dose) for 56 weeks. All
participants received recommended counseling for diet and
lifestyle modification. Study visits occurred at baseline and
weeks 2 and 4 during drug titration, and every 4 weeks
thereafter.
2.2 Effectiveness
Prior analyses [17] focused on quantifying the efficacy and
safety of Qsymia doses. Co-primary end-points were mean
weight loss from baseline and the percentage who achieved
clinically significant weight loss, defined as 5 % or greater
from baseline. We extended that analysis by computing the
incremental cost-effectiveness ratio of the recommended
dose of Qsymia relative to placebo in terms of cost per
quality-adjusted life year (QALY) gained. We focused on
the incremental cost-effectiveness of the recommended
dose as it is the most commonly prescribed dose of Qsymia
[22].
This analysis was conducted from the payer perspective,
which included the direct cost of Qsymia (assuming no
rebates, co-payments or deductibles) less cost offsets from
reductions in concomitant medications. The primary cost-
effectiveness analysis was based on the intention-to-treat
(ITT) sample, which consisted of all participants who
completed baseline measurements and surveys, were ran-
domly assigned, took at least one dose of the study drug or
placebo, and had one post-baseline bodyweight measure-
ment. Completers included a subset of these individuals
who completed the trial on the study drug or placebo and
for whom the final end-point measurement was obtained
within 7 days of the last dose (see the Electronic supple-
mentary material, ESM).
The primary measure of effectiveness was an imputed
health-related quality of life (QoL) score which was
derived from the Short Form-12 version 2 (SF-12v2) sur-
vey [23]. The SF-12v2 survey is a validated questionnaire
used to assess participant physical and mental health. We
calculated changes in the physical component summary
(PCS) and mental component summary (MCS) scales
based on the SF-12v2 survey. We used the Brazier and
Roberts algorithm [24] to convert the SF-12v2 survey into
a health-related QoL metric for each participant at baseline
and at 7 and 12 months (where 0 = dead and 1.0 = best
imaginable health state). This algorithm is widely used in
cost-effectiveness analyses [25–28]. We then estimated the
change in this metric over the trial duration, with the last
observation carried forward (LOCF) for those with missing
data. We employed a linear regression model with change
in QoL as the dependent variable and treatment arm as the
key outcome variable; sex and mean-centered baseline
QoL were included as potential confounders. Analogous
regressions were run for physical and mental health sum-
mary scores. All regression analyses were conducted using
Stata 13.1 [29].
As it is not known when the QoL benefits accrued
during the trial, we assumed that 50 % of the full benefits
accrue in the first year (i.e., they received 6 months of the
benefit). We further assumed that the benefits linearly
decayed after the medication was ceased. Our base case
assumed that individuals were on Qsymia for 1 year, with
benefits linearly decaying to zero 2 years post-drug ces-
sation. In one-way sensitivity analyses, we assumed linear
decays of 0, 1, and 3 years. We also modeled an additional
scenario whereby patients remain on Qsymia for 2 years,
with 50 % of the benefits in the first year and full benefits
in the second year, which then linearly decline to zero in
years three and four. The assumption of full benefits
through year two is supported by a follow-up study of
Qsymia which found that individuals who remained on
Qsymia for 2 years maintained the weight loss [18].
2.3 Costs
Costs and potential cost offsets for this analysis were
limited to direct costs of Qsymia, physician appointments,
and any potential cost offsets from reducing medications
for concomitant medications. Based on market prices
(September 2013), the direct cost of the recommended dose
of Qsymia is $5.12 per day [30]. Noting that a large per-
centage stopped taking their medication mid-trial (31 % in
the Qsymia recommended dose compared to 43 % in pla-
cebo), costs were allocated to participants according to how
long each remained on the medication during the first
52 weeks of the 56-week trial period. We then included
costs for two physician visits that would be expected to
occur in the first year that someone starts a prescription
weight loss drug [31].
2.4 Medication Cost Offsets
We focused on cost offsets for medications used to treat
dyslipidemia, hypertension, and type 2 diabetes, as these
CEA of Qsymia for Weight Loss 701
medications are likely to be influenced by successful
weight loss and were tracked as part of the CONQUER
trial [17]. Participants reported daily prescription medica-
tion use (dosage and name of drug) at baseline and study
conclusion. Using this information, daily medication costs
were quantified by multiplying the usage data by unit costs
for each of the reported medications. Unit costs were
obtained from Medi-Span’s PriceRx database in January
2013. The wholesale acquisition cost (WAC) was used for
branded medications, while the average WAC (AWAC)
was used for unbranded generics. Participants with no
utilization at baseline and 56 weeks were allocated a cost
of zero dollars. Baseline carried forward was used for those
missing costs at 56 weeks. We then computed the change
in daily medication costs for each class of drug and for the
three combined from baseline to 56 weeks. To identify the
impact of Qsymia on daily medication costs, we ran the
same regression as for QoL, using an ITT approach. Sim-
ilar to QoL, we did not know the exact date that changes in
medication occurred; therefore, we assumed that daily
medication savings began at month six. In future years we
assumed that all savings in concomitant medications accrue
for the entire year if participants remained on Qsymia.
2.5 Incremental Cost-Effectiveness (ICER) Ratios
We calculated incremental cost effectiveness ratios by
dividing the incremental costs of the intervention by the
incremental benefits (QALYs). As noted above, our base
case assumed individuals remained on the medication for
1 year and accrued benefits through year three. We also
considered 2 years on Qsymia, with residual benefits
accruing from years three through four. We applied a
discount rate of 3.5 % for all out-year estimates.
2.6 Sensitivity Analysis
Several sensitivity analyses were carried out. In one-way
sensitivity analyses, key inputs were varied one at a time to
simulate the impact on the incremental cost-effectiveness
ratio. Specifically, we assessed the impact of:
1. Changing the duration of benefit decay post drug
cessation from 2 years in the base case to either 0
(worst case), 1, or 3 years (best case),
2. Two years on Qsymia, with 50 % of benefits in the first
year and full benefits in the second year, linearly
declining to zero in years three and four,
3. Using the lower and upper 95 % confidence intervals
of effectiveness as estimated using converted SF-12v2
data from the trial (results available in Table 1 of the
ESM),
4. Varying prescription costs for Qsymia by ±25 %,
5. Excluding the medication offset,
6. Changing the discount rate from 3.5 to 1 % and 5 %,
and
7. Assuming no residual benefits (or costs) beyond the
trial period.
Subsequently, we employed probabilistic sensitivity
analyses on the base-case model and ran the model 1,000
times to assess the effect of uncertainty regarding the input
parameters (input values and a description of the calcula-
tions performed are available in the ESM). We assumed a
normal distribution for medication costs and for effec-
tiveness, using the estimated mean and standard deviations
from the trial data. Based on the results, we report the
percentage of iterations that fall below the $50,000 per
QALY threshold and the cost per QALY value which 95 %
of the observations fall below.
3 Results
3.1 Study Sample
Participant demographics are presented in Table 1. At base-
line, the majority of participants were female and the average
age was 51 years. Concerning comorbidities, 53 % of par-
ticipants had hypertension, 36 % had dyslipidemia, and 16 %
of the placebo group and 13.7 % of the Qsymia group had
type 2 diabetes. At baseline, average weight was roughly
103 kg and average BMI was 36.5 kg/m2. Daily medication
expenses were on average $1.19 and $1.37 for hypertension,
$1.21 and $1.38 for dyslipidemia, and $0.08 and $0.07 for
type 2 diabetes for the placebo and Qsymia arms, respec-
tively. In total, this amounted to an average $2.47 and $2.83 a
day in medication expenses for these conditions for the pla-
cebo and Qsymia arms, respectively, at baseline. There were
no significant differences in demographics or medication
costs between the study arms at baseline.
3.2 Effectiveness
As presented previously, patients receiving the Qsymia
recommended dose lost significantly more weight over the
intervention period than those receiving placebo [17]. On
average, participants taking the Qsymia recommended dose
had 6.7 kg greater weight loss than those on the placebo
(p\ 0.01) [17]. At baseline, there was no difference in
average PCS and MCS between groups (Table 2). Over the
56 weeks, both groups saw improvements in PCS scores, yet
the adjusted change in PCS was 2.28 points higher for the
Qsymia recommended group compared to the placebo group
(p\ 0.01; Table 2). There were no significant treatment
effects observed for MCS for either group. At baseline, using
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the Brazier and Roberts algorithm, the imputed QoL scores
were 0.797 and 0.803 for the placebo and Qsymia arms,
respectively. Largely due to improvements in PCS scores,
both groups saw statistically significant improvements in
QoL at 56 weeks, 0.009 and 0.027, respectively, resulting in
an adjusted improvement of 0.021 for those on Qsymia
recommended dose (p\ 0.01; Table 2).
3.3 Cost Offsets
Over the trial period, daily concomitant medication costs
per person for antihypertensive, lipid-lowering, and anti-
diabetic medications increased by $0.15 for placebo and
decreased by $0.22 for the Qsymia recommended dose
arm. This suggests a combined daily saving of $0.34 on
average for those on the Qsymia recommended dose
compared to placebo (Table 3). Annualized, this equates to
$123 in savings ($61 for the first year).
3.4 Costs
Trial data revealed that the cost of the Qsymia recom-
mended dose is $1,498 per participant for 1 year. Physician
appointments cost $89 each, for a total of $178 [31]. In the
first year, the total payer cost of the Qsymia recommended
dose (Qsymia medication costs less cost offsets) was
$1,615 per participant (Table 4).
3.5 Base-Case ICER
Using our base-case assumption of 1 year on the Qsymia
recommended dose, with 6 months of benefits in the first
year and full benefits linearly decaying to zero by the end
of year 3, the ICER is $48,340 (all ICERs rounded to the
nearest $10).
3.6 One-Way Sensitivity Analysis
In a sensitivity analysis where patients remain on the
Qsymia recommended dose for 2 years with 6 months of
benefits in the first year, full benefits in the second year,
and benefits linearly decaying to zero by the end of year
four, the ICER increases to $59,080 per QALY gained




dose (n = 488)
Age (years) 51.2 (0.33) 51.1 (0.47)
Women (%) 70.3 (0.01) 69.9 (0.02)
Baseline weight (kg) 103.3 (0.58) 102.8 (0.82)
Body mass index (kg/m2) 36.7 (0.15) 36.3 (0.2)
Co-morbidities
Hypertension (%) 52.7 (0.02) 52.5 (0.02)
Dyslipidemia (%) 35.7 (0.02) 36.7 (0.02)
Type 2 diabetes (%) 16.0 (0.01) 13.7 (0.02)
Daily medication costs
Hypertension $1.19 (0.06) $1.37 (0.1)
Dyslipidemia $1.21 (0.08) $1.38 (0.12)
Type 2 diabetes $0.08 (0.03) $0.07 (0.03)
Total $2.47 (0.11) $2.83 (0.17)
ITT intention to treat
Table 2 SF-12 Physical Health Summary Scores, Mental Health Summary Scores and quality of life for ITT, mean (SE)
SF-12 Physical Component Score (PCS) Placebo (n = 949) Qsymia recommended dose (n = 470)
Baseline 44.92 (0.27) 45.63 (0.38)
Unadjusted mean change 56 weeks with LOCF 1.58** (0.25) 3.59** (0.33)
Adjusted change with LOCF 56 weeksa 2.28** (0.38)
SF-12 Mental Component Score (MCS) Placebo (n = 949) Qsymia recommended dose (n = 470)
Baseline 53.90 (0.26) 54.14 (0.35)
Unadjusted mean change 56 weeks with LOCF -0.15 (0.24) -0.13 (0.38)
Adjusted change with LOCF 56 weeksa 0.12 (0.38)
Quality of life Placebo (n = 954) Qsymia recommended dose (n = 473)
Baseline 0.797 (0.004) 0.803 (0.005)
Unadjusted mean change 56 weeks with LOCF 0.009* (0.003) 0.027** (0.005)
Adjusted change 56 weeksa Ref. 0.021** (0.005)
LOCF last observation carried forward, ITT intention to treat
* p\ 0.05, ** p\ 0.01
a ANCOVA with change in outcome as the dependent variable and treatment arm, sex, mean-centered baseline weight, and mean-centered
baseline outcome as independent variables
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(Table 5). One-way sensitivity analyses reveal that the
assumption of benefit persistence beyond trial cessation has
the largest effect on the ICER. Assuming no residual
benefit increases the ICER from $48,340 in the base case
(2 years post cessation benefits) to $152,030, whereas
allowing for 3 years of benefits post cessation decreases the
ICER to $35,270. The ICER was also increased substan-
tially by taking the lower confidence interval of effec-
tiveness, to $96,040, or increasing the prescription costs by
25 % to $60,420 per QALY gained. Excluding the medi-
cation offset or changing the discount rate did not sub-
stantially change the ICER. One year of Qsymia with
100 % benefits and costs, assuming no post cessation
benefits, generated an ICER of $73,120 (Table 5).
3.7 Probabilistic Sensitivity Analysis
For our base case, 54 % of simulations suggest that the
cost-effectiveness of the Qsymia recommended dose
intervention relative to control is below $50,000 per
QALY, and 95 % of simulations suggest that it is below
$80,000.
3.8 Completers
Considering the completers sample, the ICER compared to
the placebo was $47,690 for the base case. Results for the
ITT and completer samples were similar because the
increased cost of the Qsymia recommended dose among
completers was similar to the increased QoL benefits
(compared to the ITT sample, costs for Qsymia were 17 %
higher and QoL benefits were 15 % greater for complet-
ers). Detailed results for completers are available in the
ESM.
4 Discussion
This paper presented the incremental cost-effectiveness
(cost per quality-adjusted life year gained) of the recom-
mended dose of Qsymia plus diet and exercise relative to
diet and exercise alone (plus placebo). While there is no
explicit threshold for what is cost-effective in the US, there
are several thresholds frequently cited as indicative of good
value for money. The most frequently cited threshold in the
US is $50,000 per QALY [32]. NICE, the agency that
makes coverage recommendations for the National Health
Service in the United Kingdom, accepts as cost-effective
those interventions with an ICER below £20,000
(US$32,000) per QALY, or £30,000 (US$48,000) per
QALY with strong reasons (£1 = USD$1.61 [33]) [34].
Our base case, which assumes individuals remain on the
drug for 1 year and that benefits linearly decay to zero in
the 2 years following drug cessation, produced an ICER for
the Qsymia recommended dose of $48,340, with probabi-
listic sensitivity analysis revealing that 54 % of our base-








Baseline ($) 2.47 (0.12) 2.83 (0.17)
Unadjusted mean change




Adjusted change with LOCF
56 weeks ($)a
Ref. -0.34* (0.09)
LOCF last observation carried forward, ITT intention to treat
* p\ 0.05, ** p\ 0.01
a ANCOVA with change in outcome as the dependent variable and
treatment arm, sex, mean-centered baseline weight, and mean-cen-
tered baseline outcome as independent variables
Table 4 Annualized recommended Qsymia costs and cost offsets for
ITT
Costs
Qsymia prescription cost $1,498
Physician appointments $178
Annualized medication cost savings -$61
Total payer perspective $1,615
Table 5 One-way sensitivity analyses ITT
ICER
Base case (1 year on Qsymia, benefits linearly decline to
zero for 2 years post medication cessation)
$48,340
Benefits linearly decline post medication cessation
0 years (no residual benefits) $152,030
1 year $74,480
3 years $35,270
Base case but 2 years on Qsymia $59,080
Effectiveness assumptionsa
Lower CI of QoL $96,040
Upper CI of QoL $32,290
Excluding medication offsets $54,120
Cost assumptions
Prescription 25 % higher than base case $60,420
Prescription 25 % lower than base case $36,250
Discount rate (base case 3.5 %)
5 % $48,980
1 % $47,260
Full costs and benefits in year 1 only $73,120
ITT intention to treat
a See Table 1 in the ESM for coefficients
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case simulations were below $50,000. Assuming a post
benefit decay of only 1 year increased the ICER to $74,480
per QALY gained. These results suggest that the Qsymia
recommended dose plus diet and exercise may be cost-
effective, depending on the time on Qsymia medication
and whether QoL benefits persist 2 years beyond medica-
tion cessation.
This analysis is based solely on the extrapolation of
within-trial results and an assumption as to how long QoL
benefits would be sustained post treatment. Because the
duration that QoL benefits persist beyond the cessation of
Qsymia is currently unknown, we modeled sensitivity
analyses ranging from no residual benefits to benefits lin-
early decaying to zero 3 years beyond medication cessa-
tion. Future research should explore the average time on
Qsymia and the duration that weight loss and QoL benefits
persist post Qsymia cessation using real-world data.
This analysis has several limitations. First, because we
do not employ a disease progression model, we cannot
model potential longer-term savings in QoL or mortality
that may result from a lower likelihood of disease pro-
gression. Second, because the Qsymia trial did not collect
data on healthcare utilization, aside from select medica-
tions, our cost offset analysis is limited to reductions in the
usage and cost of these medications. Further, there was no
significant difference in daily medication costs between the
placebo group and Qsymia recommended dose at trial
cessation. Given the lower medication cost at baseline for
the placebo arm, it is possible that the comparative
reduction in medication costs for Qsymia may reflect a
regression to the mean. However, it is also possible that
incorporating additional longer-term benefits and/or cost
offsets would suggest even greater cost-effectiveness
results than those reported here. Third, due to the trial
design, we were limited to modeling one dosage for the
entire trial period, as opposed to following clinician
guidelines for dose titration and stoppage rules. The FDA
recommends that patients should start on Qsymia 3.75 mg/
23 mg daily for 14 days, then increase to Qsymia 7.5 mg/
46 mg daily (recommended dose) for 12 weeks. If 3 %
weight loss is not achieved after 12 weeks on Qsymia
7.5 mg/46 mg dose, then it should be discontinued or
escalated to Qsymia 11.25/69 for 14 days and then Qsymia
15/92 for 12 weeks. If 5 % weight loss is not achieved after
12 weeks on the Qsymia 15/92 dose, therapy should be
discontinued as described in the label [16]. Whether or not
this recommendation is followed is unclear, but the 2013
data indicate that roughly 35 % of the volume of Qsymia is
from the Qsymia 3.75/23 dose, 56 % from the Qsymia 7.5/
46 dose, and only 9 % from the Qsymia 11.25/69 and
Qsymia 15/92 doses [22]. Due to the trial design, it is not
possible to analyze the effects of titration. We chose to
conduct the cost-effectiveness analysis focusing on the
Qsymia 7.5/46 daily dosage, herein described as the rec-
ommended dose, because in practice few patients titrate to
a higher dose after the run-in period. Finally, although our
base-case results are based on LOCF, subsequent analyses
using baseline carry forward and multiple imputation (MI)
had almost no impact on the results; QoL estimates were
identical to the fourth decimal in each case.
5 Conclusion
Given the health and cost consequences of obesity, payers
are looking to identify cost-effective treatments. These
results reveal that Qsymia may be cost-effective for over-
weight and obese individuals with two or more co-mor-
bidities if individuals remain on the drug for extended
periods and if QoL benefits are maintained post medication
cessation. Quantifying these outcomes using real-world
data should be an area of future research.
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